8-K: GRAIL Reports 52% Year-Over-Year Growth in Galleri Revenue, Reaches 250,000 Tests Sold

GRAIL, Inc. announced a 52% year-over-year increase in Galleri test revenue, reaching $25.4 million, and surpassing 250,000 tests sold since launch, while also reporting a net loss of $125.7 million for the third quarter of 2024.

Summary

• GRAIL reported a total revenue of $28.7 million for the third quarter of 2024, a 38% increase compared to the same period last year.
• Galleri test revenue reached $25.4 million, marking a 52% year-over-year growth.
• The company has sold over 250,000 Galleri tests since its launch.
• GRAIL experienced a net loss of $125.7 million for the quarter, which includes $34.6 million in amortization of Illumina acquisition-related intangible items and a $19.0 million restructuring charge.
• The gross loss for the quarter was $22.2 million.
• Non-GAAP adjusted gross profit was $11.8 million, and non-GAAP adjusted EBITDA was $(108.2) million.
• GRAIL's cash balance stands at $853.6 million as of September 30, 2024, providing a runway into 2028.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and improved net loss, but tempered by the ongoing losses and the need for regulatory approval and reimbursement. The cash runway is a positive factor.

Positives

• Galleri test sales are showing strong growth, with a 52% increase in revenue year-over-year.
• The company has achieved a significant milestone by selling over 250,000 Galleri tests since launch.
• GRAIL's cash position of $853.6 million provides a substantial runway into 2028.
• The company has improved its net loss by 86% year-over-year.
• Adjusted gross profit and adjusted EBITDA have also shown improvements year-over-year.
• The publication of Galleri test results in prostate cancer and the presentation of early results from the REFLECTION study highlight the company's progress in clinical validation.

Negatives

• GRAIL reported a net loss of $125.7 million for the quarter.
• The company experienced a gross loss of $22.2 million.
• Adjusted EBITDA remains negative at $(108.2) million.
• The net loss includes significant charges related to the Illumina acquisition and restructuring.

Risks

• The company is still operating at a loss, with a net loss of $125.7 million for the quarter.
• The company is reliant on the success of the Galleri test and its ability to gain regulatory approval and reimbursement.
• The company faces risks associated with the ongoing restructuring and its impact on operations.
• The company is subject to risks related to the competitive landscape and the development of new cancer detection technologies.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

GRAIL will continue to focus on cost management, completing registrational studies for FDA submission, and pursuing broad reimbursement for the Galleri test. The company anticipates its cash balance will provide a runway into 2028.

Management Comments

• In our first operating quarter as a public company, GRAIL continued to deliver U.S. commercial growth, with more than 250,000 Galleri tests sold as of September 30, said Bob Ragusa, Chief Executive Officer at GRAIL.
• Over the quarter, we reduced our expense base and continued to advance our mission.
• We will continue to focus on cost management as we work towards completing our registrational studies to support our U.S. FDA PMA submission and pursuing broad reimbursement.

Industry Context

The announcement reflects the ongoing efforts in the cancer detection industry to develop and commercialize early detection tests. GRAIL's focus on multi-cancer early detection aligns with the broader trend of using advanced technologies like next-generation sequencing and machine learning to improve cancer outcomes. The company's progress is being closely watched by investors and competitors in the space.

Comparison to Industry Standards

• Exact comparisons are difficult without specific competitor data, but companies like Exact Sciences (EXAS) with their Cologuard test and Guardant Health (GH) with their liquid biopsy tests are in a similar space.
• GRAIL's 52% year-over-year revenue growth for Galleri is a strong indicator of market traction, but the high net loss and negative EBITDA highlight the challenges of scaling a novel diagnostic technology.
• The cash runway into 2028 is a positive sign, but the company will need to demonstrate a clear path to profitability to be considered a long-term success.
• The positive predictive value (PPV) of 42.9% from the REFLECTION study is a key metric that will be closely watched as the company seeks regulatory approval and reimbursement.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and improved net loss, but concerned about the ongoing losses.
• Employees may be impacted by the restructuring, but the company's focus on growth and innovation is a positive sign.
• Customers (healthcare providers and patients) will benefit from the availability of the Galleri test, but its cost and reimbursement will be key factors.
• Suppliers and creditors will be interested in the company's financial stability and long-term prospects.

Next Steps

• GRAIL will continue to focus on cost management.
• The company will work towards completing registrational studies to support its U.S. FDA PMA submission.
• GRAIL will pursue broad reimbursement for the Galleri test.

Key Dates

Keywords

Galleri, Multi-Cancer Early Detection, Cancer Screening, GRAIL, Financial Results, Revenue Growth, Net Loss, EBITDA, Clinical Studies, FDA PMA Submission